Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A Rizvi, Julien Mazières, David Planchard, Thomas E Stinchcombe, Grace K Dy, Scott J Antonia, Leora Horn, Hervé Lena, Elisa Minenza, Bertrand Mennecier, Gregory A Otterson, Luis T Campos, David R Gandara, Benjamin P Levy, Suresh G Nair, Gérard Zalcman, Jürgen Wolf, Pierre-Jean Souquet, Editta Baldini, Federico Cappuzzo, Christos Chouaid, Afshin Dowlati, Rachel Sanborn, Ariel Lopez-Chavez, Christian Grohe, Rudolf M Huber, Christopher T Harbison, Christine Baudelet, Brian J Lestini, Suresh S Ramalingam

Journal: The Lancet Oncology

Publisher: Elsevier BV

Citations are the number of DOI-registered works in Crossref that cite this paper; references are how many works it cites. Full text is on the publisher site via the DOI link.